Trials that use: Log-rank test
New to this method? Read the tutorial →
220 results
- CodeBreaK 200Independent statistical analysis of CodeBreaK 200, a randomized phase 3 trial comparing AMG 510 (sotorasib) with docetaxel in KRAS G12C-mutated advanced or metastatic NSCLC, including progression-free survival, hazard ratios, confidence intervals, log-rank…
- COMBI-ADAn independent statistical analysis of the phase 3 COMBI-AD trial of dabrafenib with trametinib in high-risk BRAF V600 mutation-positive melanoma, including trial design, relapse-free survival, secondary time-to-event analyses, statistical methods, and interpretation.
- COMET-1Independent statistical analysis of COMET-1, the randomized phase 3 trial of cabozantinib versus prednisone in men with metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone or MDV3100.
- COMPASSIndependent statistical analysis of the COMPASS phase 3 trial of rivaroxaban-based antithrombotic treatment in coronary or peripheral artery disease, including trial design, time-to-event endpoints, hazard ratios, safety outcomes, statistical methods, and interpretation.
- COMPASS-2Independent statistical analysis of COMPASS-2, evaluating bosentan added to sildenafil versus sildenafil monotherapy in pulmonary arterial hypertension, including time-to-event, functional, biomarker, quality-of-life, and safety results.
- CONTACT-01Independent statistical analysis of CONTACT-01, a randomized phase 3 trial of atezolizumab plus cabozantinib versus docetaxel in metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy.
- CONTACT-03Independent statistical analysis of CONTACT-03, a randomized phase 3 trial of atezolizumab plus cabozantinib versus cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment.
- COSMIC-312Complete statistical analysis of COSMIC-312, the randomized phase 3 trial of cabozantinib plus atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma, including its time-to-event endpoints, hazard ratios, confidence intervals, p-values, and…
- COSMIC-313Independent statistical analysis of COSMIC-313, a randomized phase 3 trial of cabozantinib with nivolumab and ipilimumab versus placebo with nivolumab and ipilimumab in previously untreated advanced or metastatic renal cell carcinoma.
- COU-AA-301Independent statistical analysis of COU-AA-301, a randomized phase 3 trial of abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, covering overall survival, progression, PSA response, trial design, and statistical…
- COVACTAIndependent statistical analysis of the randomized phase 3 COVACTA trial evaluating tocilizumab versus placebo in patients with severe COVID-19 pneumonia, including endpoint definitions, reported treatment effects, confidence intervals, p-values, and statistical methodology.
- CRYSTAL-AFIndependent statistical analysis of CRYSTAL-AF, evaluating continuous cardiac monitoring with an insertable cardiac monitor for atrial fibrillation detection after cryptogenic stroke or transient ischemic attack.
- DESTINY-Breast02Complete statistical analysis of DESTINY-Breast02, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's/physician's choice in previously treated HER2-positive, unresectable and/or metastatic breast cancer.
- DESTINY-Breast04Independent statistical analysis of DESTINY-Breast04, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's choice for HER2-low breast cancer. Includes the reported progression-free survival analysis, trial design, statistical methodology, interpretation, and…
- DESTINY-Breast06Independent statistical analysis of DESTINY-Breast06 (NCT04494425), a randomized phase 3 trial comparing trastuzumab deruxtecan with investigator's choice chemotherapy in HER2-low, hormone receptor-positive, advanced or metastatic breast cancer.
- E1912Independent statistical analysis of E1912 (NCT02048813), a randomized phase 3 trial comparing ibrutinib and rituximab with fludarabine, cyclophosphamide, and rituximab in untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- ELIXAIndependent statistical analysis of the ELIXA phase 3 trial of lixisenatide versus placebo in patients with acute coronary syndrome and type 2 diabetes, including its time-to-event endpoint, non-inferiority framework, hazard ratio, confidence…
- EMBER-3Independent statistical analysis of EMBER-3, a randomized phase 3 trial of imlunestrant, investigator's choice of endocrine therapy, and imlunestrant plus abemaciclib in participants with ER+, HER2- advanced breast cancer.
- EMBRACAIndependent statistical analysis of the EMBRACA phase 3 trial of talazoparib versus physician's choice treatment in advanced and/or metastatic breast cancer patients with BRCA mutation, including progression-free survival, response, overall survival, quality…
- EMERALDIndependent statistical analysis of the phase 3 EMERALD trial of elacestrant versus standard of care in ER+/HER2- advanced breast cancer, including progression-free survival, overall survival, stratified time-to-event methods, confidence intervals, and interpretation.
- EMILIAIndependent statistical analysis of the phase 3 EMILIA trial of trastuzumab emtansine versus lapatinib plus capecitabine in HER2-positive locally advanced or metastatic breast cancer, including time-to-event methods, response analyses, safety, and interpretation.
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- EORTC 18071Independent statistical analysis of EORTC 18071, a randomized phase 3 trial of ipilimumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, distant metastasis-free survival, overall survival, and…
- EV-302Independent statistical analysis of EV-302, the randomized phase 3 trial of enfortumab vedotin plus pembrolizumab versus standard of care in untreated locally advanced or metastatic urothelial cancer.
- EVOKE-01Independent statistical analysis of EVOKE-01, a randomized phase 3 trial comparing sacituzumab govitecan with docetaxel in participants with advanced or metastatic non-small cell lung cancer, including overall survival, progression-free survival, response, patient-reported…
- ExteNETIndependent statistical analysis of the phase 3 ExteNET trial of neratinib after adjuvant trastuzumab in women with early stage breast cancer, including randomized design, time-to-event endpoints, hazard ratios, confidence intervals, survival methodology,…
- FEM-PrEPIndependent statistical analysis of FEM-PrEP, a randomized phase 3 trial evaluating Truvada versus placebo for preventing HIV acquisition in women, including its time-to-event analysis, safety endpoints, secondary outcomes, and statistical interpretation.
- FIDELIO-DKDAn independent statistical analysis of FIDELIO-DKD, the randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and diabetic kidney disease. Includes the primary renal composite, cardiovascular…
- FIGARO-DKDIndependent statistical analysis of FIGARO-DKD, a randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.
- FIRSTANAIndependent statistical analysis of the randomized phase 3 FIRSTANA trial of cabazitaxel versus docetaxel, both with prednisone, in patients with metastatic castration-resistant prostate cancer.
- FLAURAComplete statistical analysis of the phase 3 FLAURA trial of osimertinib versus standard-of-care EGFR-TKI therapy in locally advanced or metastatic EGFR sensitising mutation-positive non-small cell lung cancer.
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FOURIERIndependent statistical analysis of the FOURIER phase 3 trial of evolocumab versus placebo in subjects with elevated cardiovascular risk and dyslipidemia, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, and interpretation.
- FREEDOMIndependent statistical analysis of the FREEDOM trial comparing coronary artery bypass grafting with percutaneous coronary intervention in individuals with diabetes and multivessel coronary artery disease, including time-to-event methods, reported results, safety, and…
- FREEDOM-EVIndependent statistical analysis of FREEDOM-EV, a randomized phase 3 trial of treprostinil diolamine versus placebo in pulmonary arterial hypertension, covering clinical worsening, 6-minute walk distance, NT-proBNP, functional class, statistical methods, and safety.
- GADOLINIndependent statistical analysis of the phase 3 GADOLIN trial of obinutuzumab plus bendamustine versus bendamustine alone in participants with rituximab-refractory, indolent non-Hodgkin's lymphoma.
- GALILEOComplete statistical analysis of the GALILEO phase 3 trial comparing a rivaroxaban-based antithrombotic strategy with an antiplatelet-based strategy after transcatheter aortic valve replacement, including endpoints, hazard ratios, confidence intervals, non-inferiority analysis, safety,…
- GEMINI-ACS-1Independent statistical analysis of GEMINI-ACS-1, a randomized phase 2 trial comparing rivaroxaban with acetylsalicylic acid in addition to P2Y12 inhibitor therapy in participants with acute coronary syndrome.
- GLOWIndependent statistical analysis of the phase 3 GLOW trial of zolbetuximab plus CAPOX versus placebo plus CAPOX in CLDN 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma, including time-to-event methodology, reported efficacy results,…
- GOG-0252Independent statistical analysis of GOG-0252, a randomized phase 3 trial of bevacizumab with intravenous or intraperitoneal chemotherapy in patients with stage II-III ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- GOYAIndependent statistical analysis of the GOYA phase 3 trial of obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in participants with CD20-positive diffuse large B-cell lymphoma, including trial design, progression-free survival, statistical methodology,…
- GRIPHONIndependent statistical analysis of the GRIPHON phase 3 trial of selexipag in pulmonary arterial hypertension, covering its randomized time-to-event endpoint, secondary analyses, statistical methods, confidence intervals, and interpretation.
- HER2CLIMB-02Independent statistical analysis of HER2CLIMB-02, the randomized phase 3 trial of tucatinib with ado-trastuzumab emtansine in advanced or metastatic HER2-positive breast cancer, including time-to-event methodology, reported efficacy estimates, safety, and statistical interpretation.
- HIMALAYAComplete statistical analysis of the phase 3 HIMALAYA trial of durvalumab and tremelimumab in advanced hepatocellular carcinoma, including trial design, overall survival, non-inferiority methodology, Cox regression, log-rank testing, and interpretation.
- HVTN 702Independent statistical analysis of HVTN 702, a randomized phase 2/3 HIV vaccine prevention trial evaluating ALVAC-HIV and bivalent subtype C gp120/MF59 versus placebo, including time-to-event methods, hazard ratios, confidence intervals, safety, and…
- IBCSG 23-01Independent statistical analysis of IBCSG 23-01, a randomized trial of axillary lymph node dissection versus no axillary lymph node dissection in women with node-negative breast cancer and sentinel lymph node micrometastases.
- ICARIA-MMIndependent statistical analysis of the phase 3 ICARIA-MM trial comparing isatuximab, pomalidomide, and dexamethasone with pomalidomide and dexamethasone in refractory or relapsed and refractory multiple myeloma.
- IMblaze370Independent statistical analysis of IMblaze370, a randomized phase 3 trial comparing cobimetinib plus atezolizumab and atezolizumab monotherapy with regorafenib in metastatic colorectal adenocarcinoma.
- IMbrave050Independent statistical analysis of IMbrave050, a randomized phase 3 trial of atezolizumab plus bevacizumab versus active surveillance as adjuvant therapy in hepatocellular carcinoma at high risk of recurrence after surgical resection or…
- IMpassion130Complete statistical analysis of IMpassion130, a randomized phase 3 trial of atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated metastatic triple-negative breast cancer.